Kiniksa Pharmaceuticals International, Plc · NASDAQ:KNSA
Kiniksa Pharmaceuticals International — Q3 2025 Earnings Presentation
14 slides from Kiniksa Pharmaceuticals International's earnings presentation, Oct 28, 2025
Slide 1: Third Quarter 2025 Financial Results and Recent Portfolio Execution
Third Quarter 2025 Financial Results and Recent Portfolio Execution OCTOBER 28, 2025
Slide 2: Agenda
Agenda Introduction | Sanj K. Patel, Chief Executive Officer IL-1α & IL-1β Inhibition Franchise | Ross Moat, Chief Corporate & Commercial Officer Third Quarter 2025 Financial Results | Mark Ragosa, Chief Financial Officer Closing Remarks | Sanj K. Patel, Chief Executive Officer Q&A Session 2
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements with respect to Kiniksa Pharmaceuticals International, plc (and its consolidated subsidiaries, collectively, unless context oth
Slide 4: Introduction
Introduction Sanj K. Patel Chief Executive Officer
Slide 5: Q3 2025 Business Highlights
Q3 2025 Business Highlights Driving ARCALYST Maintaining Financial Advancing Clinical Portfolio Revenue Strength Q3 2025 ARCALYST revenue KPL-387 received US Orphan Strong financial position of $180.9M representing Drug Designation for with ~$352M in cash ~61% year-over-year growth pericarditis Curr
Slide 6: Expanding Adoption of Sustained Driving ARCALYST Sales
Expanding Adoption of Sustained IL-1α & IL-1β Inhibition Driving ARCALYST Sales Year-Over-Year Net Revenue Growth % of Prescriptions by Number of Recurrences1 $180.9M Recurrent Pericarditis Annual Epidemiology: ~40,000 1 ST RECURRENCE ~26,000 ~20% ARCALYST LABEL $112.2M 14,000 MULTIPLE RECURRENCE PO
Slide 7: IL-1α & IL-1β Inhibition Franchise
IL-1α & IL-1β Inhibition Franchise Ross Moat Chief Corporate & Commercial Officer
Slide 8: More Patients Receiving Sustained Therapy with ARCALYST
More Patients Receiving Sustained IL-1α & IL-1β Inhibition with ARCALYST Increases to active commercial patients and average total duration of therapy Total and Repeat Prescribers of ARCALYST for Recurrent Pericarditis Patients Key Revenue Drivers >3,825 ~1,275 Total Prescribers1 >3,825 >2,550 Repea
Slide 9: 2025 ARCALYST Net Product Sales Guidance
2025 ARCALYST Net Product Sales Guidance Revenue guidance raised to $670-$675M from $625-$640M $670-675M Expected Net Product Sales >$255M+ Year-over-year growth at the midpoint $417.0M $183M+ $233.2M $110M+ $122.5M $84M+ $38.5M1 2021 2022 2023 2024 2025 1) 2021 = 9 months of availability (Q2-Q4). 9
Slide 10: Advancing Leading IL-1α & IL-1β Inhibition Franchise with KPL-387
Advancing Leading IL-1α & IL-1β Inhibition Franchise with KPL-387 Treatment Phase Study Design & Type Patient Population Duration Event-Driven, Double-Blind, Pivotal Phase 3 Placebo-Controlled, Randomized- Qualifying Pericarditis Episode Event-Driven Study Withdrawal Study1 PATIENT & PHYSICIAN MARKE
Slide 11: Third Quarter 2025 Financials
Third Quarter 2025 Financials Mark Ragosa Chief Financial Officer
Slide 12: Third Quarter 2025 Financial Results
Third Quarter 2025 Financial Results Income Statement Three Months Ended September 30, Three Months Ended September 30, Collaboration Expenses1 2025 2024 2025 2024 Product Revenue $180.9M $112.2M ARCALYST Net Sales $180.9M $112.2M License and Collaboration Revenue $0.0M $0.0M Profit Split-Eligible C
Slide 13: Closing Remarks
Closing Remarks Sanj K. Patel Chief Executive Officer
Slide 14: Third Quarter 2025 Financial Results and Recent Portfolio Execution
Third Quarter 2025 Financial Results and Recent Portfolio Execution OCTOBER 28, 2025
Kiniksa Pharmaceuticals International — Q3 2025 Earnings Presentation on 6ix